Akston Biosciences Corporation is bringing innovative new biologics through the riskiest development phases, faster, more cost-effectively, and with a higher likelihood of success. Our model is well-suited for biologics development today, and will become even more valuable as U.S. payors force a reduction in the lifetime returns for innovative biologics.
Akston designed and built a multi-kilogram-scale GMP biologics factory, with full Process Development and Quality Control capabilities, all under a state-of-the-art Quality Management System.
Each of its products is derived from the Ambifect™ Fc-fusion protein platform, leveraging common manufacturing and analytical processes to speed development and reduce regulatory risk.
Akston licenses its candidates to go-to-market partners but also maintains close involvement with those partners in the product development process.
Company History
Akston is led by the team from SmartCells, Inc. that developed SmartInsulin and sold it to Merck & Co. in one of the largest preclinical pharmaceutical acquisitions in history.
While a great financial success, the team later saw how big pharma’s slow and risk-averse approach to developing this breakthrough therapeutic kept the world’s first glucose-responsive insulin from reaching the people who need it most.
With that in mind, Akston was built to bring innovative new biologics through the riskiest development phases, faster, more cost-effectively, and with a higher likelihood of success. In just over a decade, Akston has developed a strong pipeline, built its GMP manufacturing and laboratory space, and assembled a vibrant team working towards one common goal – to develop affordable, innovative medicines for everyone, everywhere in the world.